Clinical Guide to Antimicrobial Peptides: From Approved Drugs to AI-Powered Discovery
This comprehensive review covers all clinically approved AMPs, their pharmacology and mechanisms, delivery strategies, and how AI tools are accelerating discovery of next-generation antimicrobial peptides.
Quick Facts
What This Study Found
Several AMPs are already clinically approved with defined pharmacology, and emerging peptide modifications, delivery technologies, and AI-based discovery tools are expanding the therapeutic pipeline.
Key Numbers
How They Did This
Comprehensive narrative review covering AMP fundamentals, clinical pharmacology of approved AMPs, modification strategies, delivery systems, and computational discovery tools.
Why This Research Matters
AMPs are no longer just laboratory curiosities—they are approved drugs treating drug-resistant infections. Understanding the full clinical landscape helps researchers develop better ones faster.
The Bigger Picture
The AMP field has matured from basic science to clinical reality. This review maps the entire translational pipeline from natural peptide to approved drug, with AI accelerating the next wave.
What This Study Doesn't Tell Us
Broad scope limits depth on individual drugs. Rapidly evolving AI tools may quickly outdate computational sections. Not a systematic review.
Questions This Raises
- ?Which AI-designed AMPs are closest to clinical trials?
- ?Can AI predict AMP toxicity and resistance development?
- ?What regulatory pathway is optimal for modified natural AMPs?
Trust & Context
- Key Stat:
- Bench to bedside Review covers the full AMP pipeline from approved clinical drugs to AI-powered discovery of next-generation candidates
- Evidence Grade:
- Comprehensive review integrating clinical pharmacology data, modification evidence, and computational tools. Authoritative reference for the field.
- Study Age:
- Published in 2025.
- Original Title:
- Antimicrobial peptides and proteins: Mechanism of action and therapeutic potential.
- Published In:
- Advances in protein chemistry and structural biology, 149, 143-170 (2026)
- Authors:
- Dubey, Ateendra Kumar, Mishra, Amit(4), Prajapati, Vijay Kumar
- Database ID:
- RPEP-15127
Evidence Hierarchy
Frequently Asked Questions
Are antimicrobial peptides already used as medicines?
Yes, several AMPs are approved drugs used to treat infections. Examples include colistin for resistant Gram-negative bacteria and daptomycin for resistant Gram-positive infections. More are in clinical trials.
How is AI helping find new antimicrobial peptides?
AI can screen millions of potential peptide sequences, predict which ones will be antimicrobial, and even design entirely new peptides optimized for potency and safety — dramatically accelerating the discovery process.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15127APA
Dubey, Ateendra Kumar; Mishra, Amit; Prajapati, Vijay Kumar. (2026). Antimicrobial peptides and proteins: Mechanism of action and therapeutic potential.. Advances in protein chemistry and structural biology, 149, 143-170. https://doi.org/10.1016/bs.apcsb.2025.07.001
MLA
Dubey, Ateendra Kumar, et al. "Antimicrobial peptides and proteins: Mechanism of action and therapeutic potential.." Advances in protein chemistry and structural biology, 2026. https://doi.org/10.1016/bs.apcsb.2025.07.001
RethinkPeptides
RethinkPeptides Research Database. "Antimicrobial peptides and proteins: Mechanism of action and..." RPEP-15127. Retrieved from https://rethinkpeptides.com/research/dubey-2026-antimicrobial-peptides-and-proteins
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.